We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00186355
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : May 14, 2012
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Stanford University

Brief Summary:
To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.

Condition or disease Intervention/treatment
Lymphoma, Non-Hodgkin Procedure: high dose chemo then auto hematopoietic cell transplant

Detailed Description:
To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma
Study Start Date : October 2003
Primary Completion Date : March 2007
Study Completion Date : February 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Primary Outcome Measures :
  1. PCR positivity in peripheral blood cell collections after cyclophosphamide

Secondary Outcome Measures :
  1. Enrichment of hematopoietic stem cells

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:- relapsed NHL

Exclusion Criteria:- liver dysfunction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186355

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
Principal Investigator: Robert S Negrin Stanford University

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00186355     History of Changes
Other Study ID Numbers: BMT4IJ
77063 ( Other Identifier: Stanford University Alternate IRB Approval Number )
12170 ( Other Identifier: Stanford IRB )
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: May 14, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases